NewsMateria's Malta EU-GMP Approval Opens-Up European Medical Market To...

Materia’s Malta EU-GMP Approval Opens-Up European Medical Market To Firm

-

MEDICAL cannabis and CBD wellness company Materia has won EU-GMP certification for its Malta facility allowing it to begin processing and exporting cannabis flower across Europe – including the lucrative German market.

The European Union Good Manufacturing Practices (EU GMP) certification has been issued to the London-based supplier and distributor by the Malta Medicines Authority.

It has been hailed by Materia’s chief executive, Deepak Anand, as a “significant milestone.” As most European countries require the EU GMP certification for companies to import and export cannabis goods. 

Mr Anand said: “We are excited to turn the engine on and showcase the full potential of a Malta-based cannabis processor to the industry, especially global partners seeking access to the European market.”

Deepak Anand, Chief Executive Officer at Materia.

The company founded in 2018 and with a production and distribution network covering Germany, the UK, Malta and Denmark, also intends to imminently apply for a licence amendment to process cannabis extracts, leveraging the comprehensive preparatory work already completed.

Nick Pateras, Materia’s managing director, Europe, said: “We are tremendously proud to join the small group of cannabis companies with an EU GMP certified facility.

“Our team in Malta has been relentless in pursuit of this goal and adapted exceptionally to the circumstances of the last year, demonstrating why we consider them amongst the industry’s best.

“Having successfully developed our envisioned European infrastructure, commercialization now becomes our focus.” 

It took over two years for Materia to develop and prepare its Malta facility for inspection to successfully gain the EU GMP certification.

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you